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Compared clinical efficacy and bone metabolic effects of low-dose
deflazacort and methyl prednisolone in male inflammatory
arthropathies: a 12-month open randomized pilot study
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M. Bucci4, G. Cirino4 and M. Rossini5
Objective. To evaluate: (i) a correct equivalence ratio of clinical efficacy between low-dose deflazacort (DFZ) and methyl prednisolone (MP);
and (ii) bone metabolic effects of low-dose DFZ and MP in the treatment of male RA and PsA.
Methods. A total of 21 male patients with active RA or PsA, naive to steroid treatment were chosen for the study. Group I: 10 patients treated
for 6 months with DFZ 7.5 mg, calcium, cholecalciferol and a DMARD; for the following 6 months with MP 4 mg, calcium, cholecalciferol and
a DMARD. Group II: 11 patients treated for 6 months with MP 4 mg, calcium, cholecalciferol and a DMARD; for the following 6 months with
DFZ 7.5 mg, calcium, cholecalciferol and a DMARD. At day 0, 90, 180, 240 and 360 evaluation of ACR improvement criteria; a blood sample
for total and bone-specific ALP, calcium, phosphorus, PTH, SHBG, estradiol, ACTH, osteocalcin, LH, OPG; a sample of urine for calcium,
phosphorus, creatinine and DPD.
Results. 13/21 patients (6/10 Group I; 7/11 Group II) reached ACR 20 at 6 months; 14/21 (7/10 Group I, 7/10 Group II) at 12 months. Only at
the third month we observed in Group II vs Group I a reduction of OPG (24% vs 6%, P¼ n.s.); ALP (P< 0.001) and osteocalcin (P¼ 0.006)
decreased in both groups from the third month; DPD decreased in both groups only from the sixth month (P¼ 0.002).
Conclusions. The correct equivalence ratio of DFZ to MP is 1.875:1, and of DFZ to prednisolone 1.5:1. We found a relative prevalence
of bone resorption compared to bone formation in the first 6 months of treatment. The trend of OPG requires further investigation.
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Introduction
Osteoporosis is probably the most common and disabling
complication of protracted glucocorticoid (GC) treatment,
causing fractures in approximately 50% of patients treated.
Loss of bone mass is known to be more rapid in the course
of the first 6–12 months of GC treatment; probably the first
months are those with the highest osteopoenic impact, because
of excessive bone resorption [1, 2]. Glucocorticoid-induced
osteoporosis (GIO) appears to be dose-dependent [3] and is
documented for prednisolone-equivalent doses 5mg/die [4, 5].
In particular, in rheumatoid arthritis (RA) and non-axial
psoriatic arthropathy (PsA) osteoporosis can occur even in the
absence of GC treatment as a result of the action of some
mediators of chronic synovial inflammation, which are also
implicated in the genesis of osteoporosis through a mechanism
of osteoclast activation [6–9]. Osteoporosis in the course of
chronic arthritis is not only juxta-articular but also of a
generalized nature [6, 10–13].
GC acts on the bone presumably through a direct impairment
of osteoblast, osteocyte and osteoclast function, leading to
reduced bone remodelling and diminished repair of microdamage
in bone. Moreover, under GC therapy, the effects of PTH might
be more pronounced; GC antagonizes gonadal function inhibiting
the osteo-anabolic action of sex steroids; finally, GC increases
renal elimination and reduces intestinal absorption of calcium [14].
Recent data strongly implicate that this may occur through the
increased expression of the receptor that activates NF-kappa B
ligand (RANK-L) and the reduced expression of osteoprotegerin
(OPG), its soluble receptor [15–17]. Right from the start of low-
dose GC treatment, reduced serum levels have been observed for
osteocalcin (OC) and the bone isoenzyme of alkaline phosphatase
(ALP), both markers of bone neoformation, as well as for indices
of resorption [18]. In males, osteoporosis is less frequent than in
females but it is often secondary to other diseases or pharmaco-
logical treatments, in particular GC. At present, there is no
differentiation between males and females treated with GC as
regards fracture risk, but in males the morbidity and mortality
from fracture is higher due to the frequent association
of osteoporosis with another disease, most likely, the one that
triggered osteoporosis [19–23]. The androgens promote
osteoblast proliferation and differentiation and inhibit osteoclast
recruitment [24, 25]. Conversely, estradiol probably also
plays a fundamental role in males; indeed the bone effects
of testosterone are in part mediated by its conversion
to estradiol, which would act through the RANKL/OPG
pathway [26–29]. It has been observed that high plasma levels
of sex-hormone-binding-protein (SHBG) may be a predictor of
fracture risk [30].
Currently, there is debate about whether deflazacort (DFZ),
an oxazolinic derivative of prednisolone (PDN), has a lesser
calciuric and osteopoenic effect than for this reason: the 1.2:1
equipotency between DFZ and PDN, considered till now valid,
has come under criticism [31–49]. The aims of this study were the
following: primary: to validate by means of efficacy criteria the
new equivalence ratio of 1.875:1 between DFZ and methylpredni-
solone (MP), (or the DFZ to PDN ratio of 1.5:1); secondary: to
evaluate, through a cross-over study design, the bone metabolic
effects of DFZ and MP in the treatment of RA or PsA in male
GC-naive patients.
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Materials and methods
Patients
The present study, including the patient selection, was carried out
at the Rheumatology and Rehabilitation Unit of the Salvatore
Maugeri Foundation IRCCS in Castel Goffredo, Mantua, Italy.
The protocol was approved by an independent Ethics Committee
(Comitato Etico Centrale della Fondazione Salvatore Maugeri di
Pavia) and all patients enrolled gave their written informed
consent to participate in the study, obtained according to the
Declaration of Helsinki.
Inclusion criteria were as follows: males aged between 25 and
75 yrs affected by RA or PsA (only polyarthritis similar to RA
subset) as diagnosed according to ACR criteria, never treated with
GC, in a clinically active phase of the disease, in ACR functional
class 1, 2 or 3. Patients were excluded if they were: in ACR
functional class 4, under steroid treatment, currently treated with
bisphosphonates or non-substitutive androgens, or affected by
degenerative or fractural diseases of bone.
Study design
We enrolled 21 male Caucasian patients, aged between 33 and
73 yrs (mean age 60.0 11.79 yrs). Of these, 14 were affected by
RA and seven by PsA (belonging only to the subset ‘symmetric
polyarthritis similar to RA’). In 15/21 patients, the disease
duration was <8 months (12 RA, 3 PsA); the remaining
six patients (3 RA, 3 PsA) had an erosive arthritis with a mean
disease duration of 46 months; eight patients were positive for
rheumatoid factor (6 RA, 2 PsA). Concerning the activity of the
disease of the patients with PsA, they had a mean of 8.57 tender
joints and 3.42 swollen joints, while HAQ score was 0.93, all
values well within the mean of all other patients.
Patients were randomized into two groups. Group I consisted
of 10 patients (8 RA, 2 PsA, mean age 58.3 16.49 yrs) who
underwent treatment for the first 6 months with DFZ 7.5mg die
associated with bibasic calcium phosphate 3.1 g and cholecalci-
ferol 800UI; in the following 6 months, DFZ was substituted
without wash-out by MP at a dosage of 4mg die. Eight patients (7
RA, 1 PsA) were also taking methotrexate and 2 hydroxychlor-
oquine (1 RA, 1 PsA).
Group II consisted of 11 patients (6 RA, 5 PsA; mean age
59.1 5.75 yrs) who were treated for the first 6 months with MP
4mg die associated with bibasic calcium phosphate 3.1 g and
cholecalciferol 800UI; in the following 6 months MP was sub-
stituted without wash-out with DFZ at a dosage of 7.5mg die.
Seven patients (4 RA, 3 PsA) were also taking methotrexate, three
patients (2 RA, 1 PsA) hydroxychloroquine and one patient,
cyclosporin (PsA).
During the study period no intra-articular GC infiltrations
were performed, there was no variation in the GC dosage, and
there was no substitution or change in the prescribed dose of
eventual anti-inflammatory drugs in use.
All patients were assessed at the start of the study and at 3, 6,
9 and 12 months after commencement of treatment. The following
parameters were monitored: number of swollen joints; number of
tender joints; disability index calculated by means of the HAQ
questionnaire; pain measured by means of a 10 cm-long
horizontal visual analogue scale (VAS); global self-assessment of
efficacy expressed separately by the physician and patient using
a 10 cm-long horizontal VAS.
At 0 (baseline), 90, 180, 270 and 360 days, all patients
underwent blood tests and urinalysis, including 24-h urine
sampling, to determine the following parameters:
haemochrome with leucocyte formula and platelet count,
erythrocyte sedimentation rate (ESR), C-reactive-protein (CRP),
total and bone-specific ALP, protein electrophoresis, glycaemia,
glycosilated haemoglobin, uricaemia, transaminase, calcaemia/
albuminaemia, phosphoraemia, creatininaemia, plasma intact
parathyroid hormone (PTH 1-84), SHBG, estradiol, ACTH,
OC, LH, OPG, standard urine test, 24-h calciuria and phospha-
turia, creatininuria second-morning urine (before 10:00 a.m.) and
deoxypyridinoline (DPD).
Collection and storage of samples
Blood samples for the study were drawn using standard
venipuncture technique between 08:00 and 09:00 a.m. after an
overnight fast. Peripheral venous blood was drawn into sterile
vacuum blood collection tubes without any additives for serum
samples and into K3-EDTA vacutainer tubes for plasma samples
(Becton Dickinson, San Jose, CA, USA). Serum was separated
after centrifugation of blood at 48C, 1500 g for 10min.
Urine samples were obtained from a 24-h urine specimen
including the early morning portion. Patients were instructed to
collect their urine for 24 h. After division into aliquots serum,
plasma and urine samples were immediately analysed or frozen
and stored at 808C until assay and were thawed only once.
Biochemical measurements
Levels of serum and urinary calcium, creatinine and phosphate,
serum ALP, albumin and CRP, were measured using commer-
cially available kits (Olympus Diagnostici, Italy) run on an
Olympus AU400 Chemistry autoanalyser (OLYMPUS
Instruments, Japan). We corrected total serum calcium for
individual variations in albumin concentration. The intra-assay
and interassay coefficients of variation for bone-specific alkaline
phosphatase were <5 and 8%, respectively.
CRP was measured quantitatively by means of an immuno-
turbidimetric assay. Briefly, 2l of serum sample was mixed with
a 160l of a 0.05% suspension of latex particles coated with goat
anti-human CRP antibodies, in the presence of MOPSO buffer
(pH 7.5). CRP reacts specifically with anti-human CRP antibodies
to yield insoluble aggregates. The absorbance of these aggregates
detected at 800 nm is proportional to the CRP concentration in
the sample.
Bone-specific ALP was measured using agarose gel electro-
phoresis (REP, Helena Biosciences, UK).
PTH was measured by a solid-phase, two-site chemiluminescent
enzyme-labelled immunometric assay on the IMMULITE
automated analyser (Diagnostic Products Corporation,
Los Angeles, CA, USA).
Plasma OC was measured by an electrochemiluminescence
sandwich immunoassay on the fully automated analyser
Modular analytical system platform (Roche Diagnostics,
Milan, Italy). The detection limit for OC was 0.5 ng/ml, and the
intra-assay and interassay coefficients of variation ranged from
3.8% to 6.7%, respectively.
Serum OPG levels were determined using a sandwich ELISA
assay (Biovendor GmbH, Heidelberg, Germany). Briefly, in plates
coated with capture monoclonal anti-OPG antibody, samples or
OPG standard (100l) were added. Plates were incubated at room
temperature for 1 h. After washing, bound with human OPG was
detected by incubation with detection biotin labelled anti-OPG
antibody (100l) for 1 h. After washing, substrate solution was
added (100l) and determination of absorbance was obtained by
reading the plate at 450 nm. All samples were measured in
duplicate and the results were averaged. The detection limit of this
assay system was 30 pg/ml.
ESR was measured on the automatic instrument Ves-Matic 20
(DIESSE - Diagnostica Senese, Siena, Italy). The ESR reading at
the first hour was performed in 26min including the mixing of
samples.
Urine deoxypyridinoline assays were performed with a
competitive EIA method, according to the manufacturer’s
instructions and the results were corrected for urinary concentra-
tion by creatinine (Pyrilinks-D; Metra Biosystems).
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Evaluation of efficacy
To validate the equivalence ratio DFZ to MP of 1.875:1 we
evaluated the disease activity in each patient following the ACR
definition of improvement in RA: tender joints count; swollen
joints count; ESR (or CRP) levels; patient’s global assessment of
physical function using the HAQ score; patient’s assessment of
pain evaluated on an horizontal VAS scale of 10 cm; physician’s
global assessment of disease activity evaluated on a horizontal
VAS scale of 10 cm; patient’s global assessment of disease activity
evaluated on a horizontal VAS scale of 10 cm. In addition, we
considered the mean values of ESR, CRP, tender joints count,
swollen joints count, HAQ score and patient’s assessment of pain.
Monitoring of toxicity
All patients were explicitly requested at each visit to report
any eventual side effects. No biohumoral side effects emerged
from the monitoring of haemochrome, glycaemia, transaminase,
creatininaemia and urine.
Statistical analysis
Descriptive statistics were used (mean and standard deviation)
for each metabolic parameter investigated. Data were analysed by
using ANOVA for repeated measure evaluating the increase or
reduction of the parameters during the experimental time frame
independently from the group. The variation in the experimental
time frame of the parameters evaluated taking into account the
specific experimental groups.
Results
None of the 21 patients enrolled reported serious side effects.
One patient, in Group I, withdrew from the study at the third
month due to a concomitant disease not linked to either the
arthropathy or the treatment in course.
14 of the 20 patients who completed the study showed a lasting
clinical improvement according to ACR criteria: 7 were from
Group I and 7 from Group II (Table 1).
As shown in Fig. 1, there is a significant decrease of ESR, CRP,
ALP, OC, DPD that was already significant after 90 days and was
followed by a plateau, that didn’t change after the cross-over of
therapy. With regard to the indices of bone neoformation, total
ALP showed a significant decrease in both groups already at
90 days, which persisted; bone-specific ALP showed a significant
decrease in both groups, irrespective of the drug utilized;
OC showed a progressive, significant decline in both groups
that persisted throughout the study period. Among the indices
of bone resorption, urinary DPD decreased only after 180 days
(P¼ 0.002), and this persisted, with a similar trend in the two
groups.
As shown in Fig. 2, in both groups, a significant improvement
in the mean clinical parameters was already evident at the third
month of treatment; this improvement persisted throughout the
study period, independently of which GC was used. The clinical
parameters evaluated were namely: number of tender joints,
number of swollen joints, patient’s assessment of pain (VAS) and
HAQ score.
The levels of corrected serum calcium, calciuria, phosphorae-
mia and phosphaturia, LH, ACTH, PTH did not show significant
variation. In contrast, in both groups SHBG (at 90 days
P< 0.001; at 180 days P¼ 0.045) and estradiol (at 90 days,
P¼ 0.008) decreased significantly (data not shown).
Concerning OPG (Fig. 1F), although the results were not
statistically significant, a difference in trend was observed between
the two groups at 90 and 180 days. At 90 days, OPG decreased
by 6% with DFZ (Group I), and by 24% with MP (Group B).
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FIG. 1. Effect of the two different treatments, e.g. Groups I and II on the following biochemical parameters: ESR (A), CRP (B), ALP (C), OC (D), DPD (E) and OPG (F).
The data are expressed as mean S.E.M. *P< 0.05; **P<0.01, ***P<0.01 as determined by ANOVA for repeated measures.
TABLE 1. ACR improvement
Group Patients Age RA/PsA
180 days
<ACR20
180 days
>ACR20
180 days
>ACR50
180days
>ACR70
360 days
<ACR20
360 days
>ACR20
360 days
>ACR50
360 days
>ACR70
I 9 61.1 14.73 7/2 3 6 5 2 2 7 6 5
II 11 59.1 5.75 6/5 4 7 6 6 4 7 7 5
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At 180 days, the curve of Group I remained linear while in
Group II there was a sharp inversion, at the borderline of
significance (P¼ 0.06).
Discussion
The clinical efficacy of low-dose GC in combination with
DMARDs—if used appropriately already in the early phase
of the arthropathy—has recently been documented [50–52].
According to ACR criteria, here we have demonstrated the
equivalence of clinical efficacy between DFZ 7.5mg die and MP
4mg die. Indeed, a significant improvement has been found in
14 of the 20 patients that completed the study. This improvement
was independent of the GC used, was already evident at 90 days
and persisted through to the end of the study, confirming that the
equivalence ratio of DFZ to MP is 1.875:1, corresponding to 1.5:1
for that of DFZ to PDN.
Our clinical findings add support to the notion of utilizing
low-dose GC to safeguard against the potential side effects that
are dose-dependent. Cytokines have been recognized as playing
an important role in determining osteoporosis since they are
abundantly produced in the arthritic synovia, where they are the
cause of the osteo-articular damage. Thus, it should be feasible
that an effective and early anti-arthritic pharmacological inter-
vention consisting of DMARDs and low-dose GC would reduce,
rather than increase, the osteoporotic risk.
Concerning the parameters measured, we found a significant
reduction in both groups in levels of SHBG that could be
interpreted as a protective effect; indeed increase in SHBG is
considered to be a predictor of fracture risk. Another parameter
that significantly decreased in both groups after 90 days was OC
that is known to diminish in males in the course of GC treatment
as a result of the inhibitory effect of GC on osteoblasts [53].
Urinary DPD, an expression of bone resorption, declined
without difference between the groups, reaching statistical
significance only at 180 days. Thus, while the phase of reduced
bone neoformation is already evident at the third month, that
of reduced resorption occurs later and becomes apparent at
the sixth month, independently of the GC used. Consequently,
in the first months of treatment there is a relative prevalence of
resorption processes over neoformative ones, creating a type of
adverse discoupling (Fig. 1D and E).
The absence of variation in the values of PTH observed can
perhaps be attributed to the contemporary assumption of calcium
and vitamin D, but nevertheless it confirms that low-dose GC do
not cause osteopoenia through the mechanism of an increased
PTH. It is also interesting to note the stability of ACTH levels,
implying that with low-dose of GC the responsiveness of the
pituitary–adrenal axis generally remain within the normal
range [54]. On the contrary, there was a significant and early
reduction in estradiol, whose importance has been documented
also in males, as mentioned previously [26–29]. Finally, a trend in
reduction of OPG levels was evident at 90 days only in the group
using MP, followed by a sudden, almost significant inversion of
trend at 180 days (P¼ 0.06). This effect did not reach statistical
significance most likely due to the low sample size. One might
hypothesize that the reported, though controversial, lower
osteopoenic action of DFZ during the first few months of GC
treatment (considered the crucial months) is linked to the drug’s
lower impact on the relation between RANKL and OPG. Since
GIO is expressed principally during the first months of treatment,
it could be useful to verify during this period, with weekly blood
sampling and in a larger study population, the trend in OPG
utilizing different GC, including DFZ. Granted that GC are
among the most potent suppressors of OPG levels in vivo, similar
observations to ours have been recently published. In particular,
it has been shown that groups of patients utilizing for the
first time high-dose PDN showed a clear decline in OPG as early
as the first week (and a corresponding increase in sRANKL),
associated to a decline in OC [17, 27, 55]. On the other hand,
in vitro, DFZ reduces OPG less drastically than other GC [56].
If the levels of OPG in the group of MP users are decreased at
90 days from the onset of GC treatment, in the absence of
intermediate evaluations, one might hypothesize that in the
preceding weeks, in line with the above-mentioned observations,
the reduction of OPG was even more consistent; or, one
could hypothesize that the low dosage of GC we used
could have delayed the decline of OPG and consequent bone loss.
These are hypotheses that need to be verified especially if, as
recently reported, DFZ also has a protective effect on the articular
erosions typical of chronic inflammatory arthropathies. Indeed
DFZ exerts an anti-invasive and anti proliferative activity
on the rheumatoid synoviocytes through its modulating action
on the fibrinolytic system; this translates into a reduced
aggressivity of the synovial pannus and a diminished progression
of the radiologically visible damage [57].
In conclusion, we have shown that the correct equivalence ratio
of DFZ to MP is 1.875: 1 and consequently, DFZ to PDN is 1.5:1.
We have also found a relative prevalence of bone resorption
compared to bone formation in the first 6 months of treatment.
Further investigation is required on OPG; indeed the trend
observed suggest that OPG may play an important role that to be
unmasked requires a larger population sample.
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Rheumatology key messages
 The correct equivalence of deflazacort to methylprednisolone is
1.875:1 and deflazacort to prednisolone is 1.5:1.
 Low-dose of deflazacort or methylprednisolone in association with
DMARDs are both effective in the treatment of RA and PsA in
men.
 The study of bone metabolic effects of low-dose deflazacort or
methylprednisolone in male patients naive to steroid treatment
shows a relative prevalence of bone resorption compared to bone
formation in the first 6 months of treatment.
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FIG. 2. Effect of the two different treatments, e.g. Group I and Group II on the
following clinical parameters: number of tender joints (A), swollen joints (B), HAQ
score (C) and VAS score (D). The data are expressed as mean S.E.M. ***P< 0.01
as determined by ANOVA for repeated measures.
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